Release
Oslo, 11 March 2021: Scatec is pleased to invite investors, analysts and other stakeholders to our virtual Capital Markets Update: Building a global leader in renewable energy, Tuesday 23 March 2021 from 09:00 am CET to ca. 11:30 CET.
Scatec’s executive management will give an update of the company’s broadened growth strategy and targets, followed by Q&A.
To attend the Capital Markets Update, please register here
For further information, please contact:
Ingrid Aarsnes, Communication & IR, ir@scatec.com
About Scatec ASA:
Scatec is a leading renewable power producer, delivering affordable and clean energy worldwide. As a long- term player, Scatec develops, builds, owns and operates solar, wind and hydro power plants and storage solutions. The company recently acquired SN Power, a leading hydro power developer and IPP. In 2021, Scatec will have a total of 3.3 GW in operation on four continents and 485 employees. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘SCATC’. To learn more, visit www.scatec.com, or connect with us on Linkedin.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
